NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has highlighted the potential of its broad-spectrum antiviral candidate NV-387 in light of the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda. The company stated that the oral drug candidate could offer a differentiated approach if proven effective against the virus strain, emphasizing NV-387’s proposed mechanism targeting viral cell attachment pathways common across filoviruses. This positions the candidate as a potential pandemic preparedness tool for Ebola and related viral threats.
The announcement comes as the World Health Organization reports a new outbreak of the Bundibugyo ebolavirus, a less common strain of Ebola, which has caused dozens of suspected cases and deaths in the region. NanoViricides noted that NV-387 is designed to inhibit viral entry by mimicking host cell receptors, a mechanism that could be effective against multiple filoviruses, including Ebola and Marburg viruses. The drug has already shown broad-spectrum antiviral activity in preclinical studies against various viruses, including respiratory syncytial virus (RSV), influenza, and coronaviruses.
NV-387 is the company’s lead drug candidate, and it is currently being advanced toward Phase II human clinical trials. The company believes that its nanoviricide technology, which uses specially designed nanomaterials to target and destroy viruses, could provide a new approach to treating viral infections that are resistant to traditional drugs. In addition to Ebola, NanoViricides is developing drugs for a range of viral diseases, including HIV/AIDS, hepatitis B and C, rabies, herpes, influenza, dengue, and COVID-19.
The company’s platform technology is based on TheraCour nanomedicine technology, which it licenses from AllExcel. NanoViricides holds exclusive perpetual licenses for several drugs with specific targeting mechanisms for human viral diseases. The company’s business model involves licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses.
The Ebola outbreak underscores the urgent need for effective and easily deployable antiviral treatments. Current therapeutic options for Ebola are limited and often require intravenous administration, making oral drugs like NV-387 particularly attractive for outbreak settings. If successful, NV-387 could become a key component of pandemic preparedness efforts against filoviruses and other emerging viral threats.
For more information, see the full press release at https://ibn.fm/mm3Z5 and the company’s newsroom at https://ibn.fm/NNVC.
